Literature DB >> 21704361

Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets.

Hideki Fujita1, Avner Shemer, Mayte Suárez-Fariñas, Leanne M Johnson-Huang, Suzanne Tintle, Irma Cardinale, Judilyn Fuentes-Duculan, Inna Novitskaya, John A Carucci, James G Krueger, Emma Guttman-Yassky.   

Abstract

BACKGROUND: Atopic dermatitis (AD) and psoriasis represent polar immune diseases. AD is a T(H)2/T(H)22-dominant disease, whereas psoriasis is considered a T(H)1/T(H)17 disease. Local immune deviation is suggested to be regulated by dendritic cell (DC)-induced T-cell polarization and recruitment of specific T-cell subsets by chemokines. Although the role of chemokines is well documented, the actual contribution of DCs to activate polar T-cell subsets in human subjects is still a matter of speculation.
OBJECTIVE: We sought to elucidate the significance of each cutaneous DC subset in disease-specific T-cell immune deviation.
METHODS: We performed a comprehensive analysis of major cutaneous resident (Langerhans cells and blood dendritic cell antigen 1-positive dermal DCs) and inflammatory (inflammatory dendritic epidermal cells and blood dendritic cell antigen 1-negative dermal DCs) DC subsets directly isolated from the lesional skin of patients with AD and those with psoriasis.
RESULTS: The ability of each DC subset to expand T(H)1, T(H)2, T(H)17, and T(H)22 subsets was similar between the 2 diseases, despite the association of both with accumulation of resident and inflammatory DCs. We also confirmed differential upregulation of chemokine expression in patients with AD (CCL17, CCL18, and CCL22) and psoriasis (CXCL1, IL-8, and CCL20). The expression of CCL17 and CCL22 was higher in Langerhans cells from patients with AD than from patients with psoriasis, whereas the opposite was observed for CXCL9 and CXCL10.
CONCLUSION: Our results suggest that DC polarity does not directly drive differential T-cell subset responses. Alternatively, disease-specific chemokines might recruit specific memory T-cell subsets into the skin, which in turn might be activated and expanded by DCs at the site of inflammation, maintaining differential immune polarity in these diseases.
Copyright © 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704361     DOI: 10.1016/j.jaci.2011.05.016

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  35 in total

Review 1.  Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis.

Authors:  Julia K Gittler; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2012-08-28       Impact factor: 10.793

2.  Immunomodulatory effects of tacrolimus (FK506) for the treatment of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Anil Mishra
Journal:  Int J Cell Biol Physiol       Date:  2018-12-30

Review 3.  Atopic dermatitis: molecular, cellular, and clinical aspects.

Authors:  Jafar Salimian; Zahra Salehi; Ali Ahmadi; Alireza Emamvirdizadeh; Seyyed Masoud Davoudi; Mehrdad Karimi; Mohsen Korani; Sadegh Azimzadeh Jamalkandi
Journal:  Mol Biol Rep       Date:  2022-01-06       Impact factor: 2.316

Review 4.  Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis.

Authors:  Masahiro Kamata; Yayoi Tada
Journal:  Front Immunol       Date:  2022-06-28       Impact factor: 8.786

5.  Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.

Authors:  Vien Phan; Tomoki Ito; Muneo Inaba; Yoshiko Azuma; Kayoko Kibata; Noriko Inagaki-Katashiba; Akihiro Tanaka; Atsushi Satake; Shosaku Nomura
Journal:  Blood Adv       Date:  2020-08-11

Review 6.  Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.

Authors:  Nan Yang; Zeyu Chen; Xilin Zhang; Yuling Shi
Journal:  BioDrugs       Date:  2021-07-02       Impact factor: 5.807

Review 7.  Advances in atopic dermatitis.

Authors:  Natalija Novak; Donald Y M Leung
Journal:  Curr Opin Immunol       Date:  2011-10-19       Impact factor: 7.486

8.  Variants of C-C motif chemokine 22 (CCL22) are associated with susceptibility to atopic dermatitis: case-control studies.

Authors:  Tomomitsu Hirota; Hidehisa Saeki; Kaori Tomita; Shota Tanaka; Kouji Ebe; Masafumi Sakashita; Takechiyo Yamada; Shigeharu Fujieda; Akihiko Miyatake; Satoru Doi; Tadao Enomoto; Nobuyuki Hizawa; Tohru Sakamoto; Hironori Masuko; Takashi Sasaki; Tamotsu Ebihara; Masayuki Amagai; Hitokazu Esaki; Satoshi Takeuchi; Masutaka Furue; Emiko Noguchi; Naoyuki Kamatani; Yusuke Nakamura; Michiaki Kubo; Mayumi Tamari
Journal:  PLoS One       Date:  2011-11-17       Impact factor: 3.240

Review 9.  New insights into atopic dermatitis: role of skin barrier and immune dysregulation.

Authors:  Donald Y M Leung
Journal:  Allergol Int       Date:  2013-06       Impact factor: 5.836

10.  A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma.

Authors:  Michael C Peters; Lando Ringel; Nathan Dyjack; Rachelle Herrin; Prescott G Woodruff; Cydney Rios; Brian O'Connor; John V Fahy; Max A Seibold
Journal:  Am J Respir Crit Care Med       Date:  2019-02-15       Impact factor: 30.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.